文献速递肝病消化道肿瘤与早癌

癌症相关成纤维细胞介导的细胞互作支持肝细胞癌进展

Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression.
PubMed 文献 · Hepatology · 2021-01-01

本研究探讨肝细胞癌肿瘤微环境中癌症相关成纤维细胞、肿瘤细胞与肿瘤相关中性粒细胞的细胞互作。发现CAF来源的CLCF1通过CXCL6/TGF-β轴形成正反馈环路促进肿瘤干性和中性粒细胞浸润极化,抑制该信号可 impair 互作,临床样本中该轴上调与预后不良相关。

要点

  • CAF来源CLCF1通过CXCL6/TGF-β正反馈环路促进HCC进展
  • 抑制ERK1/2或CLCF1/CNTFR信号可阻断CAF-肿瘤-TAN互作
  • CLCF1-CXCL6/TGF-β轴上调与肿瘤干性、N2极化TAN及不良预后相关

核心结论

  • 本研究揭示CLCF1-CXCL6/TGF-β轴介导的细胞因子互作网络调控CAF、肿瘤干性与TAN之间的正反馈环路,影响HCC进展和患者预后。
  • 选择性阻断CLCF1/睫状神经营养因子受体或ERK1/2信号可能为HCC患者提供有效治疗靶点。

研究设计与样本

  • 本研究为基础与临床样本结合的实验研究,探究HCC肿瘤微环境中CAF、肿瘤细胞与TAN在不同阶段的细胞互作。

主要发现

  • CAF来源的CLCF1增加肿瘤细胞CXCL6和TGF-β分泌,自分泌促进肿瘤干性、旁分泌促进TAN浸润和极化。
  • HCC细胞分泌的CXCL6和TGF-β激活CAF的ERK1/2信号产生更多CLCF1,形成正反馈环路加速HCC进展。
  • 体外和体内抑制ERK1/2或CLCF1/CNTFR信号可有效 impair CLCF1介导的CAF、肿瘤细胞与TAN互作。
  • 临床样本中CLCF1-CXCL6/TGF-β轴上调与癌症干细胞增加、N2极化TAN、肿瘤分期和不良预后显著相关。

临床怎么用

  • CLCF1级联可作为HCC潜在预后生物标志物。
  • 选择性阻断CLCF1/CNTFR或ERK1/2信号可能成为HCC治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cancer-associated fibroblasts (CAFs) are key players in multicellular, stromal-dependent alterations leading to HCC pathogenesis. However, the intricate crosstalk between CAFs and other components in the tumor microenvironment (TME) remains unclear. This study aimed to investigate the cellular crosstalk among CAFs, tumor cells, and tumor-associated neutrophils (TANs) during different stages of HCC pathogenesis. APPROACH AND RESULTS: In the HCC-TME, CAF-derived cardiotrophin-like cytokine factor 1 (CLCF1) increased chemokine (C-X-C motif) ligand 6 (CXCL6) and TGF-β secretion in tumor cells, which subsequently promoted tumor cell stemness in an autocrine manner and TAN infiltration and polarization in a paracrine manner. Moreover, CXCL6 and TGF-β secreted by HCC cells activated extracellular signal-regulated kinase (ERK) 1/2 signaling of CAFs to produce more CLCF1, thus forming a positive feedback loop to accelerate HCC progression. Inhibition of ERK1/2 or CLCF1/ciliary neurotrophic factor receptor signaling efficiently impaired CLCF1-mediated crosstalk among CAFs, tumor cells, and TANs both in vitro and in vivo. In clinical samples, up-regulation of the CLCF1-CXCL6/TGF-β axis exhibited a marked correlation with increased cancer stem cells, "N2"-polarized TANs, tumor stage, and poor prognosis. CONCLUSIONS: This study reveals a cytokine-mediated cellular crosstalk and clinical network involving the CLCF1-CXCL6/TGF-β axis, which regulates the positive feedback loop among CAFs, tumor stemness, and TANs, HCC progression, and patient prognosis. These results may support the CLCF1 cascade as a potential prognostic biomarker and suggest that selective blockade of CLCF1/ciliary neurotrophic factor receptor or ERK1/2 signaling could provide an effective therapeutic target for patients with HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Song M, He J, Pan QZ, et al. Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. Hepatology. 2021. PMID: 33682185. doi:10.1002/hep.31792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。